Skip to content

Use of Apheretic Technologies in Cardiovascular Disease

Use of H.E.L.P. Apheresis in Patients With High Cardiovascular Disease Lp(a)-Related

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02380534
Enrollment
0
Registered
2015-03-05
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Keywords

High level of Lp(a)

Brief summary

To evaluate the effects of H.E.L.P. apheresis on lipid profile, Lp(a) level, and some inflammatory adypocytokines in patients with high cardiovascular risk.

Interventions

PROCEDUREH.E.L.P. apheresis

High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.

Sponsors

Fondazione IRCCS Policlinico San Matteo di Pavia
CollaboratorOTHER
University of Pavia
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* high Lp(a) not responsive to diet and pharmacological treatment

Exclusion criteria

* heart failure * hepatic failure * renal failure

Design outcomes

Primary

MeasureTime frameDescription
Lp(a) reduction1 yearWe will evaluate the efficacy of apheretic technique through the reduction of Lp(a) in the plasma sample expressed by mg/dL.

Secondary

MeasureTime frameDescription
Inflammatory adypocytokines1 yearWe will evaluate the efficacy of apheretic technique through the improvement of inflammatory adypocytokines in the plasma sample.

Other

MeasureTime frameDescription
Lipid profile1 yearWe will evaluate the efficacy of apheretic technique through the reduction of total cholesterol, LDL and HDL cholesterol, and triglycerides in the plasma sample expressed by mg/dL.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026